| Literature DB >> 22549283 |
R Harpaz1, W DuMouchel, N H Shah, D Madigan, P Ryan, C Friedman.
Abstract
An important goal of the health system is to identify new adverse drug events (ADEs) in the postapproval period. Datamining methods that can transform data into meaningful knowledge to inform patient safety have proven essential for this purpose. New opportunities have emerged to harness data sources that have not been used within the traditional framework. This article provides an overview of recent methodological innovations and data sources used to support ADE discovery and analysis.Entities:
Mesh:
Year: 2012 PMID: 22549283 PMCID: PMC3675775 DOI: 10.1038/clpt.2012.50
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN: 0009-9236 Impact factor: 6.875